EUVIMEDEUVIMED entdecken
Crossref

PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer

Shunan Zhang, Yi Lai, Jiaxing Pan, Madiha Saeed, Shiqin Li, Huiling Zhou, Xingyu Jiang, Jing Gao, Yun Zhu, Haijun Yu iD, Wen Zhang, Zhiai Xu

Advanced Materials · 2024

DOI: 10.1002/adma.202314132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Shunan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China. Hauptthemen laut MEDLINE: Prodrugs, Radiation-Sensitizing Agents, Transcription Factors, Nanoparticles. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Science and Technology Commission of Shanghai Municipality, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation therapy (RT) is one of the primary options for clinical cancer therapy, in particular advanced head and neck squamous cell carcinoma (HNSCC). Herein, the crucial role of bromodomain‐containing protein 4 (BRD4)‐RAD51 associated protein 1 (RAD51AP1) axis in sensitizing RT of HNSCC is revealed. A versatile nanosensitizer (RPB7H) is thus innovatively engineered by integrating a PROteolysis TArgeting Chimeras (PROTAC) prodrug (BPA771) and hafnium dioxide (HfO 2 ) nanoparticles to downregulate BRD4‐RAD51AP1 pathway and sensitize HNSCC tumor to RT. Upon intravenous administration, the RPB7H nanoparticles selectively accumulate at the tumor tissue and internalize into tumor cells by recognizing neuropilin‐1 overexpressed in the tumor mass. HfO 2 nanoparticles enhance RT effectiveness by amplifying X‐ray deposition, intensifying DNA damage, and boosting oxidative stress. Meanwhile, BPA771 can be activated by RT‐induced H 2 O 2 secretion to degrade BRD4 and inactivate RAD51AP1, thus impeding RT‐induced DNA damage repair. This versatile nanosensitizer, combined with X‐ray irradiation, effectively regresses HNSCC tumor growth in a mouse model. The findings introduce a PROTAC prodrug‐based radiosensitization strategy by targeting the BRD4‐RAD51AP1 axis, may offer a promising avenue to augment RT and more effective HNSCC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsRadiation-Sensitizing AgentsTranscription FactorsNanoparticlesAnimalsHumansCell Line, TumorMiceCell Cycle ProteinsProteolysisSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsDNA DamageNeuropilin-1Bromodomain Containing Proteins

Stichwörter der Autor:innen

PROTAC prodrugactive tumor targetingnanosensitizerradiation therapytumor microenvironment

Substanzen

ProdrugsRadiation-Sensitizing AgentsTranscription FactorsCell Cycle ProteinsBRD4 protein, humanNeuropilin-1Bromodomain Containing Proteins

Autor:innen und Institutionen

  • School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
  • State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 2000092, China.
  • Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.

ORCID-Profile: Haijun Yu

Förderung

  • National Natural Science Foundation of China
  • the Science and Technology Commission of Shanghai Municipality
  • China Postdoctoral Science Foundation
  • China National Postdoctoral Program for Innovative Talents
  • Lingang Laboratory
  • biobank program of Shanghai ninth people's hospital
  • Shanghai Professional Technology Service Platform on Cold Chain Equipment Performance and Energy Saving Evaluation

Zitieren

APA

Zhang, S., Lai, Y., Pan, J., Saeed, M., Li, S., Zhou, H., Jiang, X., Gao, J., Zhu, Y., Yu, H., Zhang, W., & Xu, Z. (2024). PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer. Advanced Materials. https://doi.org/10.1002/adma.202314132

Vancouver

Zhang S, Lai Y, Pan J, Saeed M, Li S, Zhou H, et al. PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer. Advanced Materials. 2024. doi:10.1002/adma.202314132

BibTeX
@article{Zhang2024,
  author = {Zhang, Shunan and Lai, Yi and Pan, Jiaxing and Saeed, Madiha and Li, Shiqin and Zhou, Huiling and Jiang, Xingyu and Gao, Jing and Zhu, Yun and Yu, Haijun and Zhang, Wen and Xu, Zhiai},
  title = {PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202314132}
}
Kostenlos starten →